{"id":"W4311018682","doi":"10.1200/jco.22.01065","title":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Cilag; NIHR Cambridge Biomedical Research Centre; Genentech; National Institutes of Health; Ipsen; MorphoSys; Astellas Pharma; Eisai; National Institute for Health and Care Research; Cancer Research UK; Merck KGaA; ECOG-ACRIN Cancer Research Group; BeiGene; Medical Research Council; Les Laboratories Pierre Fabre; TG Therapeutics; Daiichi-Sankyo; Celldex Therapeutics; Celgene; NRG Oncology; American College of Radiology Imaging Network; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Oncosuisse; GlaxoSmithKline; National Cancer Research Institute; National Health and Medical Research Council; EUSA Pharma; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Plexxikon; Relay Therapeutics; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Amgen; Breast Cancer Research Foundation; Sanofi","keywords":"Exemestane; Tamoxifen; Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Gynecology; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01666911,0.001017461,0.002927286,0.001551505,0.0003647914,0.001668333,0.0005932935,0.001098145,0.005210628],"category_scores_gemma":[0.01552772,0.0002882957,0.005601724,0.001884211,0.0005489638,0.001494866,0.001277876,0.002055961,0.001125721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007137345,"about_ca_system_score_gemma":0.000915026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008453388,"about_ca_topic_score_gemma":0.002812638,"domain_scores_codex":[0.9943728,0.003008913,0.0008187365,0.0004038159,0.001076237,0.0003194178],"domain_scores_gemma":[0.9812599,0.00799787,0.006350848,0.001524923,0.00172052,0.001146068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4393389,0.003444502,0.07744887,0.0234372,0.05137029,0.0002895201,0.0003700703,0.002992987,0.004892931,0.0009245684,0.01577333,0.3797169],"study_design_scores_gemma":[0.07084042,0.1531324,0.6013386,0.008294855,0.09562032,0.001475641,0.0004808509,0.002246247,0.005474887,0.0029473,0.057832,0.0003164176],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6762209,0.2642536,0.004250761,0.003619466,0.001293727,0.001813935,0.02642433,0.0002713783,0.02185196],"genre_scores_gemma":[0.8876808,0.06573327,0.003683076,0.00296776,0.002147491,0.001740776,0.02833411,0.0001354768,0.007577295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01666911,"threshold_uncertainty_score":0.08815575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04385691293835649,"score_gpt":0.389506704370043,"score_spread":0.3456497914316865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}